Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2029-04-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4